William Blair Initiates Coverage on Insulet (NASDAQ:PODD)

Equities researchers at William Blair initiated coverage on shares of Insulet (NASDAQ:PODD) in a research note issued on Wednesday. The brokerage set an “outperform” rating on the medical instruments supplier’s stock.

A number of other equities research analysts have also commented on the stock. Evercore lowered their price target on shares of Insulet from $240.00 to $200.00 in a report on Thursday, May 7th. Citigroup decreased their price objective on shares of Insulet from $230.00 to $175.00 in a research report on Thursday, May 7th. Benchmark assumed coverage on shares of Insulet in a research note on Tuesday, May 12th. They set a “buy” rating for the company. Leerink Partners dropped their target price on shares of Insulet from $360.00 to $247.00 in a report on Thursday, May 7th. Finally, Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 price target (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Twenty-one analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $254.96.

Insulet Trading Up 0.6%

NASDAQ PODD traded up $0.99 during trading on Wednesday, hitting $155.60. 62,101 shares of the company’s stock traded hands, compared to its average volume of 1,131,296. The stock has a fifty day moving average of $196.51 and a two-hundred day moving average of $254.15. Insulet has a 12-month low of $145.59 and a 12-month high of $354.88. The firm has a market cap of $10.78 billion, a P/E ratio of 36.28, a PEG ratio of 1.24 and a beta of 1.20. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. During the same quarter in the previous year, the company posted $1.02 EPS. Insulet’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, sell-side analysts expect that Insulet will post 6.44 EPS for the current year.

Insider Buying and Selling at Insulet

In related news, Director Michael R. Minogue acquired 2,030 shares of the stock in a transaction on Wednesday, February 25th. The stock was acquired at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the purchase, the director owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.36% of the stock is owned by insiders.

Institutional Investors Weigh In On Insulet

Several institutional investors and hedge funds have recently made changes to their positions in the company. Larson Financial Group LLC boosted its stake in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in Insulet in the 4th quarter worth about $26,000. Elyxium Wealth LLC purchased a new position in Insulet in the 4th quarter worth about $28,000. DV Equities LLC bought a new position in Insulet during the 4th quarter valued at about $28,000. Finally, MV Capital Management Inc. purchased a new stake in shares of Insulet during the 4th quarter valued at about $29,000.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.